Recruiting

Observational Study

Sponsor:

Alimentiv Inc.

Code:

NCT06670638

Conditions

Crohns Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

To date, patients with Crohn's Disease (CD) and permanent ileostomies have been excluded from clinical trials for new treatments. To allow this patient population to be included in clinical trials, outcome and measurement tools are needed. This study aims to develop a Patient Reported Outcome (PRO) and Endoscopic Index (EI) for patients with Crohn's Disease (CD) and permanent ileostomy. The study will enroll about 50 participants and collect videos of endoscopies that are done as part of standard of care. The videos will be centrally read to identify features that represent a broad range of inflammation and will be used to develop the EI. Participants will also be asked to participate in interviews, to understand the symptoms and impacts that are most important to participants for the development of a PRO.

Conditions

Crohns Disease

Study ID

NCT06670638

Start date

Jun 19, 2024

Status verified date

Nov, 2025

Completion date

Feb 28, 2027

Anticipated

Primary completion date

Jun 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Adults (age ≥ 18 years) with a diagnosis of CD treated surgically with subtotal colectomy/proctocolectomy end ileostomy at least 12 months prior to the scheduled endoscopy procedure.
2. Planning to have an ileoscopy procedure scheduled as part of routine medical care.
3. Be proficient in the English language (ie, ability to read, write, speak, and understand English well enough to take part in the interview process without the aid of an interpreter).
4. Able and willing to participate fully in all aspects of this study.
5. Written informed consent must be obtained and documented.

Exclusion Criteria:

1. End or loop colostomy, end ileostomy for UC, continent ileostomy, ileal pouch anal anastomosis, end ileostomy with mucous fistula, double barrel ileostomy, urostomy, loop ostomy, or any type of end ileostomy not considered permanent at the time of enrolment (with no intent to restore continuity).
2. Peristomal skin complications such as pyoderma gangrenosum, abscess, or any other severe peristomal skin inflammation.
3. Stomal stenosis obviating ileoscopy, known small bowel stricture, major stoma prolapse, symptomatic parastomal hernia, parastomal hernia with subcutaneous loops of small bowel within the hernia, stoma in a crease/poorly fitting applicable resulting in severe peristomal skin irritation, or retracted stoma that prevents endoscopic evaluation.
4. Any actively draining fistula (eg, peristomal or peri-anal).
5. Evidence of a known small bowel stricture on cross-sectional imaging or inability to pass an endoscope within the past 6 months.
6. Known active Clostridoides difficile or other enteric infection.
7. Short bowel syndrome.
8. Predominant symptom(s) arising from a retained rectal stump.
9. Serious underlying disease other than CD that in the opinion of the investigator may interfere with the participant's ability to participate fully in the study procedures or provide nonconfounded descriptions of their CD and ostomy symptom experiences during the interview.
10. Prior enrolment in the current study.

Study Design

Enrollment

50 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Develop a PRO instrument for patients with Crohn's Disease and Permanent Ileostomy [ Time Frame: through study completion, and average of 1 year ]
  • Evaluate the intrarater reliability of 100-mm VAS. [ Time Frame: At baseline and 2 weeks ]
  • Evaluate the intrarater reliability of RAM identified items. [ Time Frame: At baseline and 2 weeks ]
  • Evaluate the intrarater reliability of Rutgeerts score and its component items. [ Time Frame: At baseline and 2 weeks ]
  • Evaluate the intrarater reliability of CDEIS and its component items. [ Time Frame: At baseline and 2 weeks ]
  • Evaluate the intrarater reliability of SES-CD and its component items. [ Time Frame: At baseline and 2 weeks ]
  • Evaluate the interrater reliability of 100-mm VAS. [ Time Frame: At baseline ]
  • Evaluate the interrater reliability of RAM identified items. [ Time Frame: At baseline ]
  • Evaluate the interrater reliability of Rutgeerts score and its component items. [ Time Frame: At baseline ]
  • Evaluate the interrater reliability of CDEIS and its component items. [ Time Frame: At baseline ]
  • Evaluate the interrater reliability of SES-CD and its component items. [ Time Frame: At baseline ]
  • Develop a novel index using a multiple regression approach with the dependent variables being the VAS and candidate independent variables including items having at least moderate interrater reliability. [ Time Frame: through study completion, and average of 1 year ]

Central Contacts and Locations

Locations

Mayo Clinic- Rochester

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Principal Investigator:

David Bruning

Washington University in St Louis School of Medicine

Recruiting

St Louis, Missouri, United States, 63110

Contacts

Principal Investigator:

Parakkal Deepak

Cleveland Clinic Foundation

Recruiting

Cleveland, Ohio, United States, 44195

Contacts

Catherine Larson

larsenc@ccf.org

Principal Investigator:

Florian Rieder

McMaster University Medical Centre

Recruiting

Hamilton, Ontario, Canada, L6S 0E2

Contacts

Principal Investigator:

Neeraj Narula

LHSC - University Campus

Recruiting

London, Ontario, Canada, L6S 0E2

Contacts

Principal Investigator:

Vipul Jairath

More Information

Sponsor

Alimentiv Inc.

Last update posted

Nov 12, 2025

Last verified

Nov, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-26. This information was provided to ClinicalTrials.gov by Alimentiv Inc. on 2025-11-12. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.